The effect of selenium and zinc on CD4(+) count and opportunistic infections in HIV/AIDS patients: a randomized double blind trial

Abstract

<b>Objectives</b>: We assessed the effect of selenium and zinc supplementation on CD4 cell count and the risk of developing opportunistic infections.<b>Methods</b>: In a double blind clinical trial, 146 HIV(+) patients receiving combination antiretroviral therapy with CD4(+) >200/cubic millimeter were screened for comorbidities and opportunistic infections, and randomized to receive daily selenium (200 µg), zinc (50 mg) or placebo for 6 months, before a 3-month follow-up period. CD4 cell counts were measured in the 3^th, 6^th and 9^th months. The serum selenium and zinc were measured in the 6^th month. The incidence of opportunistic infection was assessed monthly for 6 months and at the end of the 9^th month.<b>Results</b>: The final incidence of supplement deficiency for placebo, zinc and selenium were 46.7%, 44.7% and 50.0%, respectively. Overall compliance with supplementation was 99.42%. Although the changes from baseline were not statistically significant, zinc supplementation was significantly associated with reduced risk of opportunistic infections.<b>Conclusion</b>: Development of the opportunistic infections after zinc supplementation significantly decreased; however, significant improvement in CD4 count was not observed in this group.